Interim 18F-fluorodeoxyglucose positron emission tomography in diffuse large B-cell lymphoma: Qualitative or quantitative interpretation where do we stand? Diffuse large B-cell lymphoma M. Meignan et al.

Leukemia and Lymphoma

Volumn 50, Issue 11, 2009, Pages 1753-1756

  Meignan, Michel ^a   Itti, Emmanuel ^a   Gallamini, Andrea ^b   Haioun, Corinne ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Diffuse large B cell lymphoma; Interim PET; Lymphoma; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT;

CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; LARGE CELL LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; ARTICLE; HUMAN; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 71049138078     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903308056     Document Type: Conference Paper

References (18)

1. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin lymphoma. Haematologica 2000;85:613-618.
2. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin lymphoma. Ann Oncol 2002;13:1356-1363.
3. Haioun C, Itti E, Rahmouni A, et al. [18F]Fluoro-2-deoxy-Dglucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 2005;106:1376-1381.
4. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005;16: 1514-1523.
5. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002;43: 1018-1027.
6. Cheson B. The case against heavy PETing. J Clin Oncol 2009;27:1742-1743.
7. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma: A systematic review. J Clin Oncol 2009;27:1906-1914.
8. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25: 571-578.
9. Han HS, Escalon MP, Hsiao B, et al. High incidence of falsepositive PET scans in patients with aggressive non-Hodgkin' lymphoma treated with rituximab-containing regimens. Ann Oncol 2009;20:309-318.
10. Kostakoglu L. Early prediction of response to therapy: The clinical implications in Hodgkin and non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 2008;35:1413-1420.
11. Dupuis J, Gaulard P, Hemery F, et al. Respective prognostic values of germinal center phenotype and early (18)Fluorodeoxyglucose- positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. Haematologica 2007;92:778-783.
12. Lin C, Itti E, Haioun C, et al. Early 18F-FDG-PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626-1632.
13. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating 18fluorodeoxyglucose positron emission tomography to the international workshop criteria. Ann Oncol 2009; 20:503-507.
14. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18f- FDG-PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527-533.
15. Gallamini A, Hutchings M, Avigdor A, et al. Early interim PET scan in Hodgkin lymphoma: Where do we stand? Leuk Lymphoma 2008;49:659-662.
16. Horning SJ, Juweid M, Schoder H, et al. Interim positron emission tomography (PET) in diffuse large B-cell lymphoma: Independent expert nuclear medicine evaluation of ECOG 3404. Blood 2008;112:372 (Abstract).
17. Meignan M, Itti E, Bardet S, et al. Development and application of a real-time on-line blinded independent central review of interim pet scans to determine treatment allocation in lymphoma trials. J Clin Oncol 2009;27:2739-2741.
18. Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkins and non-Hodgkin' lymphoma. Curr Opin Oncol 2008;20:206-219.